^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

1476P - Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study

Published date:
09/05/2022
Excerpt:
The Meet-URO 18 study is a multicenter study assessing the I-TME in mRCC pts treated with ≥2nd line nivolumab divided according to clinical benefit in responders versus non-responders (progression-free survival ≥ 12 vs ≤ 3 months, respectively)....Responders (N = 55) presented lower expression of CD4 and higher levels of ph-mTOR and CD56 compared to non responders. Responders showed also a tendency towards higher CD3 expression (≥40: 73% vs 56%, p=0.059) and CD8/CD4 ratio (median 1.74 vs 1.20, p=0.084).